Imunon, Inc.’s Promising Study on IMNN-001 for Ovarian Cancer: A Market Perspective

Imunon, Inc. ((IMNN)) announced an update on their ongoing clinical study.

Imunon, Inc. is conducting a clinical study titled ‘A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.’ The study aims to assess the safety and efficacy of IMNN-001 combined with standard chemotherapy in treating advanced ovarian cancer, a significant step in cancer treatment research.

The intervention being tested is IMNN-001, a biological treatment formulated with IL-12 plasmid, intended to enhance the efficacy of chemotherapy in treating ovarian cancer. It is administered intraperitoneally alongside standard chemotherapy drugs, Carboplatin and Paclitaxel.

This interventional study follows a randomized, parallel assignment model without masking, focusing primarily on treatment. It compares the effects of the experimental combination of IMNN-001 and NACT against NACT alone in a multicenter setting.

The study began on September 5, 2018, and is currently active but not recruiting. The last update was submitted on July 1, 2025. These dates are crucial for tracking the study’s progress and its impact on clinical practices.

The ongoing study has potential implications for Imunon, Inc.’s stock performance, as positive results could enhance investor confidence and market position. The study’s outcome may also influence the competitive landscape in the oncology sector, particularly in ovarian cancer treatment.

The study is ongoing, with further details available on the ClinicalTrials portal.